

Publications

Complete Skin Clearance and PASI response rates in clinical practice- Predictors, Health Related Quality of Life improvements and implications for treatment goals.

Norlin JM, Nilsson K, Persson U, Schmitt-Egenolf M.

Br J Dermatol. 2019 Jul 20. doi: 10.1111/bjd.18361. [Epub ahead of print]

<https://www.ncbi.nlm.nih.gov/pubmed/31325318>

Methotrexate Management in Psoriasis: Are We Following the Guidelines?

Lindqvist T, Salah LA, Gillstedt M, Wennberg AM, Osmancevic A.

Acta Derm Venereol. 2018 Apr 16;98(4):449-451

www.ncbi.nlm.nih.gov/pubmed/29199349

Sustained PASI, DLQI and EQ-5D response of biologic treatment in psoriasis: 10 years of real-world data in the Swedish National Psoriasis Register

F Hjalte, K Steen Carlsson, M Schmitt-Egenolf

Br J Dermatol. 2018 Jan;178(1):245-252

www.ncbi.nlm.nih.gov/pubmed/28644904

How is disease severity associated with quality of life in psoriasis patients? Evidence from a longitudinal population-based study in Sweden

Geale K, Henriksson M, M Schmitt-Egenolf

Health Qual Life Outcomes. 2017 Jul 28;15(1):151

www.ncbi.nlm.nih.gov/pubmed/28754116

Severity of psoriasis differs between men and women - a registry based study of the clinical outcome measure Psoriasis Area and Severity Index (PASI) in 4045 patients

D Hägg, M Eriksson, A Sundström, M Schmitt-Egenolf

Am J Clin Dermatol. 2017 Aug;18(4):583-590

www.ncbi.nlm.nih.gov/pubmed/28342016

Real-world outcomes in 2,646 psoriasis patients:

One in five has PASI \geq 10 and/or DLQI \geq 10 under ongoing systemic therapy

J M Norlin, U Persson, M Schmitt-Egenolf

J Dermatolog Treat. 2017 Sep;28(6):500-504

www.ncbi.nlm.nih.gov/pubmed/28132580

Regional differences in the prescription of biologics for psoriasis in Sweden: a register-based study of 4,168 patients

P S Calara, R Althin, K Steen Carlsson, M Schmitt-Egenolf

BioDrugs. 2017 Feb;31(1):75-82

www.ncbi.nlm.nih.gov/pubmed/28097638

A Retrospective Study of Patients with Psoriasis Treated with Biologics: Relation to Body Mass Index and Gender.

Salah LA, Gillstedt M, Osmancevic A

Acta Derm Venereol. 2016 Nov 2;96(7):974-975

www.ncbi.nlm.nih.gov/pubmed/27120180

Healthcare provider and switch to biologics in psoriasis:
evidence from real world practice
P S Calara, J M Norlin, R Althin, K Steen Carlsson, U Persson,
M Schmitt-Egenolf
BioDrugs. 2016 Apr;30(2): 145-51
www.ncbi.nlm.nih.gov/pubmed/26883786

Register-Based Evaluation of Relative Effectiveness of New Therapies:
Biologics Versus Conventional Agents in Treatment of Psoriasis in Sweden.
J M Norlin, K Steen Carlsson, U Persson, M Schmitt-Egenolf
BioDrugs. 2015 Dec; 29(6): 389-98
www.ncbi.nlm.nih.gov/pubmed/26670179

Evaluating equality in psoriasis healthcare: a cohort study of the impact of age on
prescription of biologics
K Geale M, Henriksson, M Schmitt-Egenolf
The British journal of dermatology 2016 Mar;174(3): 579-87
www.ncbi.nlm.nih.gov/pubmed/26616003

Real-World Outcome Analysis of Continuously and Intermittently Treated Patients with
Moderate to Severe Psoriasis after Switching to a Biologic Agent
Hjalte F, Steen Carlsson K, M Schmitt-Egenolf
Dermatology. 2015; 230 (4): 347-53
www.ncbi.nlm.nih.gov/pubmed/25721571

Decision for biological treatment in real life is more strongly associated with the Psoriasis
Area and Severity Index (PASI) than with the Dermatology Life Quality Index (DLQI)
D Hägg, M Eriksson, A Sundström, M Schmitt-Egenolf
J Eur Acad Dermatol Venereol. 2015 Mar; 29(3): 452-6
www.ncbi.nlm.nih.gov/pubmed/24911993

Resource use in patients with psoriasis after the introduction of biologics in Sweden -
Direct costs increase, whereas indirect costs decrease
J M Norlin, K Steen Carlsson, U Persson, M Schmitt-Egenolf
Acta Derm Venereol. 2015 Feb;95(2):156-61
www.ncbi.nlm.nih.gov/pubmed/24819980

(Register studies measure the effectiveness of drugs in clinical practice) Kvalitetsregister
för att mäta effektivitet av läkemedel i klinisk praxis –
exempel ifrån PsoReg
J M Norlin, M Schmitt-Egenolf, K Steen Carlsson, U Persson,
Läkartidningen 2014 24:2014 p. 1061-63
www.ncbi.nlm.nih.gov/pubmed/25129915

The higher proportion of men with psoriasis treated with biologics may be explained by
more severe disease in men
D Hägg, M Eriksson, A Sundström, M Schmitt-Egenolf
PLoS One. 2013 May 15;8(5):e63619
www.ncbi.nlm.nih.gov/pubmed/23691076

Switch to Biologic Agent in Psoriasis Significantly Improved Clinical and Patient Reported Outcomes in Real-World Practice

J M Norlin, K Steen Carlsson, U Persson, M Schmitt-Egenolf
Dermatology. 2012; 225(4):326-32
www.ncbi.nlm.nih.gov/pubmed/23328678

Gender and the treatment of immune-mediated chronic inflammatory diseases: Rheumatoid arthritis, inflammatory bowel disease and psoriasis: an observational study.

Lesuis N, Befrits R, Nyberg F, van Vollenhoven RF
BMC Med. 2012 Aug 1;10:82.
www.ncbi.nlm.nih.gov/pubmed/22853635

Challenges for synthesising data in a network of registries for systemic psoriasis therapies
A D Ormerod, M Augustin, C Baker, O Chosidow, A D Cohen, T N Dam, I Garcia-Doval, L L Lecluse, M Schmitt-Egenolf, P I Spuls, K D Watson, L Naldi

Dermatology. 2012;224(3):236-43
www.ncbi.nlm.nih.gov/pubmed/22678413

Analysis of Three Outcome Measures in Moderate to Severe Psoriasis - A Registry Based Study of 2.450 Patients

J M Norlin, K Steen Carlsson, U Persson, M Schmitt-Egenolf
The British journal of dermatology. 12/2011; 166(4):797-802
www.ncbi.nlm.nih.gov/pubmed/22182212

National Registries of Systemic Treatment for Psoriasis and the European 'Psonet' Initiative
Lecluse LLA, Naldi L, Stern R, Spuls PI, for the Psonet study network

Dermatology (Basel, Switzerland). 01/2009; 218(4):347-56
www.ncbi.nlm.nih.gov/pubmed/19077384

PsoReg -- the Swedish registry for systemic psoriasis treatment. The registry's design and objectives

M Schmitt-Egenolf
Dermatology (Basel, Switzerland). 02/2007; 214(2):112-7.
www.ncbi.nlm.nih.gov/pubmed/17341858

Psoriasis therapy in real life: the need for registries

M Schmitt-Egenolf
Dermatology (Basel, Switzerland). 02/2006; 213(4):327-30
www.ncbi.nlm.nih.gov/pubmed/17135739